|
|
|
|
|
Sponsored by: |
Genentech |
Information provided by: | Genentech |
ClinicalTrials.gov Identifier: | NCT00388206 |
This is an observational study designed to follow patients with metastatic or locally advanced and unresectable CRC, locally advanced or metastatic NSCLC (excluding predominant squamous histology) who are receiving Avastin in combination with first-line chemotherapy. Second-line metastatic CRC patients are also eligible. Patients who started their Avastin containing therapy <3 months prior to enrollment are eligible.
Condition | Phase |
Colorectal Cancer Non-Small Cell Lung Cancer |
Phase IV |
MedlinePlus related topics: | Cancer Colorectal Cancer Lung Cancer |
ChemIDplus related topics: | Bevacizumab |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Cancer and Locally Advanced or Metastatic Non-Small Cell Lung (Excluding Predominant Squamous Cell Histology) |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: The AIRES Call Center | 866-903-4465 | ariesregistry@wilm.ppd.com |
Show 249 Study Locations |
Genentech |
Study Director: | Mary Sugrue, M.D. | Genentech |
Responsible Party: | Genentech, Inc. |
Study ID Numbers: | AVF3991n |
First Received: | October 12, 2006 |
Last Updated: | March 20, 2008 |
ClinicalTrials.gov Identifier: | NCT00388206 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|
|